Compare TYL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYL | UTHR |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 23.9B |
| IPO Year | 1996 | 1999 |
| Metric | TYL | UTHR |
|---|---|---|
| Price | $350.74 | $527.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $478.91 | ★ $531.79 |
| AVG Volume (30 Days) | ★ 559.9K | 485.2K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.01 | 13.07 |
| EPS | 7.20 | ★ 27.86 |
| Revenue | $493,101,000.00 | ★ $1,483,300,000.00 |
| Revenue This Year | $9.63 | $7.77 |
| Revenue Next Year | $9.66 | $11.11 |
| P/E Ratio | $47.79 | ★ $19.04 |
| Revenue Growth | ★ 18.35 | 2.38 |
| 52 Week Low | $283.72 | $266.98 |
| 52 Week High | $621.34 | $548.12 |
| Indicator | TYL | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 57.52 |
| Support Level | $320.23 | $464.92 |
| Resistance Level | $373.88 | $542.66 |
| Average True Range (ATR) | 11.40 | 14.24 |
| MACD | 1.32 | 1.62 |
| Stochastic Oscillator | 20.40 | 74.46 |
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.